financetom
Business
financetom
/
Business
/
--B. Riley Securities Adjusts Beazer Homes USA's PT to $38 From $42, Keeps Buy Rating
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--B. Riley Securities Adjusts Beazer Homes USA's PT to $38 From $42, Keeps Buy Rating
May 2, 2024 6:29 AM

09:02 AM EDT, 05/02/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Price: 28.60, Change: +0.40, Percent Change: +1.42

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
IBM to invest $150 billion in US over next five years
IBM to invest $150 billion in US over next five years
May 25, 2025
April 28 (Reuters) - IBM ( IBM ) on Monday announced plans to invest $150 billion in the U.S. over the next five years. ...
Eton Pharmaceuticals Submits NDA to FDA for ET-600 to Treat Central Diabetes Insipidus
Eton Pharmaceuticals Submits NDA to FDA for ET-600 to Treat Central Diabetes Insipidus
May 25, 2025
08:30 AM EDT, 04/28/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Monday it submitted a new drug application to the US Food and Drug Administration for ET-600, its proprietary oral solution of desmopressin developed to treat central diabetes insipidus. The company said it expects a standard 10-month review, potentially leading to approval and launch in Q1 2026. ET-600...
Consumer watchdog lifts Well Fargo consent order in regulatory relief for lender
Consumer watchdog lifts Well Fargo consent order in regulatory relief for lender
May 25, 2025
April 28 (Reuters) - The Consumer Financial Protection Bureau (CFPB) has lifted a 2018 consent order related to Wells Fargo's ( WFC ) compliance risk management, the bank said on Monday, signaling progress in resolving the lender's outstanding regulatory issues. This was the sixth consent order for the bank that regulators have closed in 2025, Wells said. Today's termination, along...
Copyright 2023-2026 - www.financetom.com All Rights Reserved